Stem Cell Innovations, Inc. has filed a patent application protecting the differentiation of its proprietary human pluripotent stem cells (PCs) into neural progenitor cells and purified populations of motor neurons. These cells will initially be used in the company's core drug discovery and toxicology platform. The company is also exploring therapeutic applications of these cells.
Dr. James Kelly, CEO of Stem Cell Innovations, Inc. (SCI), stated, "These cells have significant potential in both drug discovery and cell therapies to treat diseases such as ALS, Parkinson's, Huntington's, Multiple Sclerosis, and Spinal Cord Injury. Obtaining and protecting neural progenitor cells, as well as purified populations of motor neurons from our PCs, is a significant step for the company." Kelly added, "We are already in discussions with companies that have expressed interest in these cells."
Stem Cell Innovations is actively seeking to make its PC cells widely available to universities and other not-for-profit institutions to rapidly advance the potential of the cells for the benefit of people and the company.
Subscribe via RSS
